Assistant Professor of Pharmacy Practice, University of Toledo, College of Pharmacy and Pharmaceutical Sciences, Department of Pharmacy Practice, 3000 Arlington Avenue Mail Stop 1013, Toledo, OH 43614, United States.
Pulm Pharmacol Ther. 2018 Apr;49:119-122. doi: 10.1016/j.pupt.2018.02.003. Epub 2018 Feb 15.
Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death in the United States. Guideline recommendations for medication therapy include the use of inhaled medications for management of stable COPD. There are limited data available describing prescribing percentages of medications in patients with COPD.
To determine the prescribing percentages of medications for COPD in a national, cross-sectional study.
This was a national, cross-sectional study using data from the National Ambulatory Medical Care Survey (NAMCS) in 2013. Patients were included if they had an International Classification of Diseases (ICD) 9 code for COPD and were greater than 18 years of age. Data describing patient demographics, provider demographics and prescribed medications were collected. Data were analyzed using sample weights to account for the multi-stage sample design.
On weighted analysis, 15,821,000 patient visits were included. Patients were predominantly female, greater than 40 years of age and white, non-Hispanic. The most common provider type was primary care provider. At least one COPD medication was prescribed to 64.8% of included patients. Prescription of short-acting bronchodilators was most common in this cohort and observed at a percentage of 42.5%. A long-acting bronchodilator or inhaled corticosteroid was prescribed to 32.3% of included patients. The most common long-acting bronchodilator used was long-acting beta-agonist therapy in 21.3% of patients.
This study describes patients with COPD from a nationally representative sample. The percentage of maintenance medication prescribing indicates further opportunity for medication optimization in the outpatient setting for patients with COPD.
慢性阻塞性肺疾病(COPD)是美国的第三大死亡原因。药物治疗指南建议使用吸入药物来管理稳定期 COPD。目前,关于 COPD 患者药物处方比例的描述性数据有限。
通过全国性横断面研究,确定 COPD 患者的药物处方比例。
这是一项全国性的横断面研究,使用了 2013 年国家门诊医疗调查(NAMCS)的数据。纳入的患者需要有 COPD 的国际疾病分类(ICD)9 编码,且年龄大于 18 岁。收集描述患者人口统计学特征、提供者人口统计学特征和处方药物的数据。使用样本权重进行数据分析,以考虑多阶段样本设计。
加权分析共纳入 1582.1 万例患者就诊。患者主要为女性,年龄大于 40 岁,且为白人非西班牙裔。最常见的提供者类型是初级保健提供者。至少有 1 种 COPD 药物被开给了 64.8%的纳入患者。该队列中短效支气管扩张剂的处方最为常见,占比为 42.5%。长效支气管扩张剂或吸入性皮质类固醇被开给了 32.3%的纳入患者。最常用的长效支气管扩张剂是长效β激动剂治疗,占 21.3%的患者。
本研究描述了来自全国代表性样本的 COPD 患者。维持药物处方的比例表明,在 COPD 患者的门诊环境中,进一步有机会优化药物治疗。